Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | TP53 | P04637 | 3/20 | 0.66 |
| ▸ | CDKN1A | P38936 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.48 |
| ▸ | HPGD | P15428 | 6/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | EGFR | P00533 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17903557 | 0.83 | MAPT (0.70) | MAPTSMN1; SMN2TP53CDKN1ARAB9A | |
| SCHEMBL15614744 | 0.82 | MAPT (0.66) | MAPTSMN1; SMN2TP53CDKN1ARAB9A | |
| SCHEMBL17903714 | 0.80 | MAPT (0.63) | MAPTSMN1; SMN2TP53CDKN1ARAB9A | |
| SCHEMBL15614714 | 0.80 | MAPT (0.62) | MAPTSMN1; SMN2TP53CDKN1ARAB9A | |
| SCHEMBL17903191 | 0.79 | MAPT (0.62) | MAPTSMN1; SMN2TP53CDKN1ARAB9A | |
| SCHEMBL15614757 | 0.79 | MAPT (1.00) | MAPTSMN1; SMN2TP53CDKN1ARAB9A | |
| SCHEMBL3040691 | 0.79 | MAPT (0.62) | MAPTSMN1; SMN2TP53CDKN1ARAB9A | |
| SCHEMBL20569976 | 0.79 | TP53 (0.60) | MAPTSMN1; SMN2TP53CDKN1ARAB9A | |
| SCHEMBL23657898 | 0.77 | MAPT (0.54) | MAPTSMN1; SMN2TP53CDKN1ARAB9A | |
| SCHEMBL3040696 | 0.74 | MAPT (0.58) | MAPTSMN1; SMN2TP53CDKN1ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG (DE) | 2015-07-30 | — | — | US | disclosed |
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | LEIBNIZ-INSTITUT FÜR ALTERSFORSCHUNG (DE) | 2015-07-30 | — | — | US | disclosed |
| WO-2014041125-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | BADEN-WÜRTTEMBERG STIFTUNG GMBH (DE) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210717-A1 | SPECIFIC INHIBITORS OF PROTEIN P21 AS THERAPEUTIC AGENTS | CDKN1A, ING2, BCCIP | MAPT 4589/4885SMN1; SMN2 2018/4885TP53 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.